Literature DB >> 25548130

Regorafenib: start low and go slow.

S Tabchi1, M Ghosn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25548130     DOI： 10.1007/s11523-014-0352-7

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


× No keyword cloud information.
  9 in total

1.  A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.

Authors:  Klaus Mross; Annette Frost; Simone Steinbild; Susanne Hedbom; Martin Büchert; Ulrike Fasol; Clemens Unger; Jörn Krätzschmar; Roland Heinig; Oliver Boix; Olaf Christensen
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

2.  Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.

Authors:  Scott M Wilhelm; Jacques Dumas; Lila Adnane; Mark Lynch; Christopher A Carter; Gunnar Schütz; Karl-Heinz Thierauch; Dieter Zopf
Journal:  Int J Cancer       Date:  2011-04-22       Impact factor: 7.396

3.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.

Authors:  H J Schmoll; E Van Cutsem; A Stein; V Valentini; B Glimelius; K Haustermans; B Nordlinger; C J van de Velde; J Balmana; J Regula; I D Nagtegaal; R G Beets-Tan; D Arnold; F Ciardiello; P Hoff; D Kerr; C H Köhne; R Labianca; T Price; W Scheithauer; A Sobrero; J Tabernero; D Aderka; S Barroso; G Bodoky; J Y Douillard; H El Ghazaly; J Gallardo; A Garin; R Glynne-Jones; K Jordan; A Meshcheryakov; D Papamichail; P Pfeiffer; I Souglakos; S Turhal; A Cervantes
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

4.  Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

Authors:  Alexander Stein; Wieland Voigt; Karin Jordan
Journal:  Ther Adv Med Oncol       Date:  2010-01       Impact factor: 8.168

5.  Recommended guidelines for the treatment of cancer treatment-induced diarrhea.

Authors:  Al B Benson; Jaffer A Ajani; Robert B Catalano; Constance Engelking; Steven M Kornblau; James A Martenson; Richard McCallum; Edith P Mitchell; Thomas M O'Dorisio; Everett E Vokes; Scott Wadler
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

6.  Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.

Authors:  Axel Grothey; Suzanne George; Eric van Cutsem; Jean-Yves Blay; Alberto Sobrero; George D Demetri
Journal:  Oncologist       Date:  2014-05-12

7.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

8.  The current state of targeted agents in rectal cancer.

Authors:  Dae Dong Kim; Cathy Eng
Journal:  Int J Surg Oncol       Date:  2012-05-17

9.  Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics.

Authors:  Yu Sunakawa; Junji Furuse; Takuji Okusaka; Masafumi Ikeda; Fumio Nagashima; Hideki Ueno; Shuichi Mitsunaga; Kensei Hashizume; Yuichiro Ito; Yasutsuna Sasaki
Journal:  Invest New Drugs       Date:  2013-04-04       Impact factor: 3.850
  9 in total
  8 in total

1.  Comment on: "Regorafenib: Start Low and Go Slow".

Authors:  Christelle de la Fouchardière
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493

2.  Author's Reply to Christelle de la Fouchardière: "Regorafenib: Start Low and Go Slow".

Authors:  Samer Tabchi; Marwan Ghosn
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493

3.  Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.

Authors:  Eric Van Cutsem; Erika Martinelli; Stefano Cascinu; Alberto Sobrero; Maria Banzi; Jean-François Seitz; Carlo Barone; Marc Ychou; Marc Peeters; Baruch Brenner; Ralf Dieter Hofheinz; Evaristo Maiello; Thierry André; Andrea Spallanzani; Rocio Garcia-Carbonero; Yull E Arriaga; Udit Verma; Axel Grothey; Christian Kappeler; Ashok Miriyala; Joachim Kalmus; Alfredo Falcone; Alberto Zaniboni
Journal:  Oncologist       Date:  2018-09-06

4.  Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis.

Authors:  Alessandro Rizzo; Margherita Nannini; Marco Novelli; Angela Dalia Ricci; Valerio Di Scioscio; Maria Abbondanza Pantaleo
Journal:  Ther Adv Med Oncol       Date:  2020-07-07       Impact factor: 8.168

Review 5.  Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

Authors:  B McLellan; F Ciardiello; M E Lacouture; S Segaert; E Van Cutsem
Journal:  Ann Oncol       Date:  2015-06-01       Impact factor: 32.976

Review 6.  Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug?

Authors:  Gaurav Goel
Journal:  Cancer Manag Res       Date:  2018-03-06       Impact factor: 3.989

7.  Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.

Authors:  Margherita Nannini; Maria Concetta Nigro; Bruno Vincenzi; Elena Fumagalli; Giovanni Grignani; Lorenzo D'Ambrosio; Giuseppe Badalamenti; Lorena Incorvaia; Raffaella Bracci; Silvia Gasperoni; Maristella Saponara; Lidia Gatto; Valentina Indio; Annalisa Astolfi; Valerio Di Scioscio; Paolo G Casali; Giuseppe Tonini; Massimo Aglietta; Antonio Russo; Guido Biasco; Maria A Pantaleo
Journal:  Ther Adv Med Oncol       Date:  2017-12-19       Impact factor: 8.168

8.  Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series.

Authors:  José Luis Leal; Juan Briones; María Elisa Herrera; Bettina Müller; Bruno Nervi; Sebastián Mondaca
Journal:  Ecancermedicalscience       Date:  2018-10-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.